Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001848548 | SCV002105441 | uncertain significance | Hereditary spastic paraplegia | 2020-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002074417 | SCV002404802 | benign | Hereditary spastic paraplegia 45 | 2023-10-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002543413 | SCV003548991 | uncertain significance | Inborn genetic diseases | 2021-01-20 | criteria provided, single submitter | clinical testing | The c.540-4G>A intronic alteration consists of a G to A substitution 4 nucleotides before coding exon <NA> in the NT5C2 gene. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |